Skip to main content

Advertisement

SpringerLink
Log in

Is Pazopanib Safe and Efficacious in Patients with Metastatic Renal Cell Carcinoma?

  • Clinical Trial Report
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005, 23:1028–1043.

    Article  CAS  PubMed  Google Scholar 

  2. Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991–5004.

    Article  CAS  PubMed  Google Scholar 

  3. •• Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007, 356:115–124. This phase 3 trial compared sunitinib and interferon-α in patients with advanced RCC.

    Article  CAS  PubMed  Google Scholar 

  4. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125–134.

    Article  CAS  PubMed  Google Scholar 

  5. Kumar R, Harrington LE, Hopper TM, et al.: Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice. J Clin Oncol 2005, 23:846s.

    Article  Google Scholar 

  6. •• Hurwitz HI, Dowlati A, Saini S, et al.: Phase I trial of pazopanib (GW786034), an oral multikinase angiogenesis inhibitor, in patients with advanced cancer: results of safety, pharmacokinetics, and clinical activity. Clin Cancer Res 2009, 15:4220–4227. This article discusses a phase 1 trial of pazopanib in solid tumor patients.

    Article  CAS  PubMed  Google Scholar 

  7. Escudier B, Pluzanska A, Koralewski P, et al.: Bevacizumab plus interferon alfa-2A for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet 2007, 370:2103–2111.

    Article  PubMed  Google Scholar 

  8. Karaman MW, Herrgard S, Treiber DK, et al.: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127–132.

    Article  CAS  PubMed  Google Scholar 

  9. Kumar R, Knick VB, Rudolph SK, et al.: Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6:2012–2021.

    Article  CAS  PubMed  Google Scholar 

  10. Sternberg, CN, Szczylik C, Lee ES, et al.: A randomized, double-blind phase lll study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009, 27:15s.

    Article  Google Scholar 

  11. US Food and Drug Administration: FDA labeling information for Votrient (pazopanib) tablets. Revised October 2009. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf. Accessed December 29, 2009.

Download references

Disclosure

Dr. Bukowski has received honoraria from Pfizer, Novartis, Wyeth, and Bayer as a member of their speaker bureaus, and from Novartis, Pfizer, Bayer, and GlaxoSmithKline as a consultant.

Author information

Authors and Affiliations

  1. Taussig Cancer Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, R35, Cleveland, OH, 44195, USA

    Ronald M. Bukowski

Authors
  1. Ronald M. Bukowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald M. Bukowski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bukowski, R.M. Is Pazopanib Safe and Efficacious in Patients with Metastatic Renal Cell Carcinoma?. Curr Oncol Rep 12, 77–79 (2010). https://doi.org/10.1007/s11912-010-0082-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-010-0082-7

Keywords

Search

Navigation